<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fennec Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc</link>
<description>Latest news and press releases for Fennec Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fennec-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683569da78dffbe2df0f1ef4.webp</url>
<title>Fennec Pharmaceuticals Inc</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc</link>
</image>
<item>
<title>Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-acceptance-of-abstracts-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-acceptance-of-abstracts-at-the-2026-asco-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-university-of-arizona-cancer-center</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-university-of-arizona-cancer-center</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty</description>
</item>
<item>
<title>Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product</description>
</item>
<item>
<title>Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-settlement-agreement-resolving-pedmark-patent-litigation</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-settlement-agreement-resolving-pedmark-patent-litigation</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company,</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-clinical-research-collaboration-with-tampa-general-hospital-cancer-institute</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-clinical-research-collaboration-with-tampa-general-hospital-cancer-institute</guid>
<pubDate>Wed, 04 Mar 2026 12:05:00 GMT</pubDate>
<description>Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin ChemotherapyRESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study</description>
</item>
<item>
<title>Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-presents-real-world-data-supporting-the-integration-and-clinical-use-of-pedmarkr-in-treating-adults-with-head-and-neck-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-presents-real-world-data-supporting-the-integration-and-clinical-use-of-pedmarkr-in-treating-adults-with-head-and-neck-cancers</guid>
<pubDate>Fri, 20 Feb 2026 12:03:00 GMT</pubDate>
<description>– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK® to Address Cisplatin-Induced Hearing Loss, a Critical Survivorship Gap, Without Compromising Cisplatin’s Established Antitumor Activity – – Majority of High-Risk Patients Receiving PEDMARK® Demonstrated No Measurable Hearing Loss During or After Treatment Desp</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-investigator-sponsored-120000283</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-investigator-sponsored-120000283</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Receiving Cisplatin-Based Chemotherapy – RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the planned initiation of an investigator-sp</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-positive-topline-120100177</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-positive-topline-120100177</guid>
<pubDate>Tue, 02 Dec 2025 12:01:00 GMT</pubDate>
<description>– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – – PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate – – The Company Plans to Pursue Registration and is Exploring Partnering or Licensi</description>
</item>
<item>
<title>Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-participate-piper-sandler-105900874</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-participate-piper-sandler-105900874</guid>
<pubDate>Wed, 26 Nov 2025 10:59:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast. Webcast Detail: Date:Wednesday, December 3, 2025Time:1:00 p.m. Eastern TimeWebcast Link:https://event.webcasts.com/starthere.jsp?ei</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-completion-full-120300962</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-completion-full-120300962</guid>
<pubDate>Wed, 19 Nov 2025 12:03:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company’s previously announced underwritten public offering in the United States and concur</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-closing-private-133000220</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-closing-private-133000220</guid>
<pubDate>Tue, 18 Nov 2025 13:30:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of US$5,025,000. The offering was made to prospective purchasers resident in any province in Canada (except Que</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Closing of Offering of Common Shares</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-closing-offering-211500348</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-closing-offering-211500348</guid>
<pubDate>Mon, 17 Nov 2025 21:15:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters’ option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec’s total gross proceeds from the offering (before deductin</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-private-offering-041100171</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-private-offering-041100171</guid>
<pubDate>Fri, 14 Nov 2025 04:11:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to the Compa</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-pricing-offering-040700456</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-pricing-offering-040700456</guid>
<pubDate>Fri, 14 Nov 2025 04:07:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 700,000 common shares on the same terms and conditions. Fennec anticipate</description>
</item>
<item>
<title>Fennec Pharmaceuticals Announces Proposed Offering of Common Shares</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-proposed-offering-210800868</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-announces-proposed-offering-210800868</guid>
<pubDate>Thu, 13 Nov 2025 21:08:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares sold in the public offering. Fennec intends to use the net proceeds of the pr</description>
</item>
<item>
<title>Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-reports-third-quarter-210100660</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-reports-third-quarter-210100660</guid>
<pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
<description>~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results Expected in Q4 2025 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2025 and provided a business up</description>
</item>
<item>
<title>Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-reports-second-quarter-100800449</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-reports-second-quarter-100800449</guid>
<pubDate>Thu, 14 Aug 2025 10:08:00 GMT</pubDate>
<description>~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany with Additional EU Launches Planned ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Hal</description>
</item>
<item>
<title>Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025</title>
<link>https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-report-second-quarter-111200074</link>
<guid isPermaLink="true">https://6ix.com/company/fennec-pharmaceuticals-inc/news/fennec-pharmaceuticals-report-second-quarter-111200074</guid>
<pubDate>Mon, 11 Aug 2025 11:12:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date: Thurs</description>
</item>
</channel>
</rss>